These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 34118855)

  • 21. Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Serum Electrolyte Levels in Patients with Type 2 Diabetes: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials.
    Zhang J; Huan Y; Leibensperger M; Seo B; Song Y
    Kidney360; 2022 Mar; 3(3):477-487. PubMed ID: 35582188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
    Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
    Mazidi M; Rezaie P; Gao HK; Kengne AP
    J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28546454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
    Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
    Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.
    Li D; Wang T; Shen S; Fang Z; Dong Y; Tang H
    Diabetes Obes Metab; 2017 Mar; 19(3):348-355. PubMed ID: 27862830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials.
    Jiang Y; Yang P; Fu L; Sun L; Shen W; Wu Q
    Front Endocrinol (Lausanne); 2022; 13():802992. PubMed ID: 35370961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum uric acid lowering and effects of sodium-glucose cotransporter-2 inhibitors on gout: A meta-analysis and meta-regression of randomized controlled trials.
    Banerjee M; Pal R; Maisnam I; Chowdhury S; Mukhopadhyay S
    Diabetes Obes Metab; 2023 Sep; 25(9):2697-2703. PubMed ID: 37334516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis.
    Xin Y; Guo Y; Li Y; Ma Y; Li L; Jiang H
    Saudi J Biol Sci; 2019 Feb; 26(2):421-426. PubMed ID: 31485187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Seidu S; Kunutsor SK; Topsever P; Khunti K
    Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.
    Musso G; Gambino R; Cassader M; Pagano G
    Ann Med; 2012 Jun; 44(4):375-93. PubMed ID: 21495788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
    Chen Z; Li G
    Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Zou H; Liu L; Guo J; Wang H; Liu S; Xing Y; Deng C; Xiao Y; Zhou Z
    J Diabetes Investig; 2021 Apr; 12(4):546-556. PubMed ID: 33245620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Mori Y; Duru OK; Tuttle KR; Fukuma S; Taura D; Harada N; Inagaki N; Inoue K
    J Clin Endocrinol Metab; 2022 Dec; 108(1):221-231. PubMed ID: 36217306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.
    Tang H; Li D; Zhang J; Li Y; Wang T; Zhai S; Song Y
    Diabetes Obes Metab; 2017 Aug; 19(8):1106-1115. PubMed ID: 28240446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Xing B; Zhao Y; Dong B; Zhou Y; Lv W; Zhao W
    J Diabetes Investig; 2020 Sep; 11(5):1238-1247. PubMed ID: 32083798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SGLT inhibitors on weight and body mass: A meta-analysis of 116 randomized-controlled trials.
    Cheong AJY; Teo YN; Teo YH; Syn NL; Ong HT; Ting AZH; Chia AZQ; Chong EY; Chan MY; Lee CH; Lim AYL; Kong WKF; Wong RCC; Chai P; Sia CH
    Obesity (Silver Spring); 2022 Jan; 30(1):117-128. PubMed ID: 34932882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Davies MJ; Patsko E; Dhalwani NN; Kloecker DE; Ioannidou E; Gray LJ
    Diabetes Obes Metab; 2020 Jul; 22(7):1035-1046. PubMed ID: 32077218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.
    Wang H; Yang J; Chen X; Qiu F; Li J
    Clin Ther; 2019 Feb; 41(2):322-334.e11. PubMed ID: 30711143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.